Matches in SemOpenAlex for { <https://semopenalex.org/work/W2548332911> ?p ?o ?g. }
- W2548332911 endingPage "279" @default.
- W2548332911 startingPage "271" @default.
- W2548332911 abstract "BackgroundTuberculosis/Human Immunodeficiency Virus (TB/HIV) is a very common co-infection which carries a high mortality rate. Though World Health Organization recommends co-treatment of TB/HIV to improve its outcome, Rifampicin potentially induces metabolism and sub-therapeutic antiretroviral plasma levels of non nucleoside reverse transcriptase inhibitors and protease inhibitors which may cause inadequate virological suppression if corrections are not timely done. In Tanzania Therapeutic drug monitoring is not done; so the proportion of sub-therapeutic ARV plasma levels among TB/HIV patients co-treated with anti-tuberculous drugs is not known. The aim of this study was therefore to determine the magnitude and risk factors of sub-therapeutic ARV plasma levels among adult HIV patients co-treated with anti tuberculous Medications.Materials and methodsA cross sectional hospital based study was conducted among adult HIV patients on ARV and TB co-treatment for at least one month. Patients were serially enrolled through routine HIV care and treatment services until the sample size was reached. The information about demographic, clinical and adherence level, Anti-TB duration, viral load, baseline and enrollment CD4 counts, Hepatitis B co-infection and ARV plasma levels was collected and analyzed using STATA 12 software.ResultsIn total 118 patients were included in this study; of whom 26 (22%) had sub-therapeutic ARV plasma levels. The sub-therapeutic ARV levels were independently associated with adherence <95% (OR = 6.8, p = 0.001), female gender (OR = 3.4, p = 0.028) and virological failure (OR = 3.8, p = 0.016). NVP based regimen was associated with sub-therapeutic drug levels on univariate model (OR = 2.1, p = 0.010).ConclusionThe magnitude of sub-therapeutic ARV plasma levels is high among adult HIV/TB co-infected patients on anti-TB co-treatment in Tanzania. These patients stand a high risk of inadequate virological suppression with a potential resistance development and a long term poor clinical outcome. Identifying at risk patients and adherence enhancement could potentially improve the overall outcome of this subgroup of patients in resource restricted setting like ours where TDM is not available." @default.
- W2548332911 created "2016-11-11" @default.
- W2548332911 creator A5013929805 @default.
- W2548332911 creator A5037590928 @default.
- W2548332911 creator A5049722680 @default.
- W2548332911 creator A5078046174 @default.
- W2548332911 creator A5086760804 @default.
- W2548332911 creator A5091425909 @default.
- W2548332911 date "2017-08-01" @default.
- W2548332911 modified "2023-09-26" @default.
- W2548332911 title "Sub therapeutic drug levels among HIV/TB co-infected patients receiving Rifampicin in northwestern Tanzania: A cross sectional clinic based study" @default.
- W2548332911 cites W1586759857 @default.
- W2548332911 cites W1971773192 @default.
- W2548332911 cites W1998739651 @default.
- W2548332911 cites W2004353492 @default.
- W2548332911 cites W2010296039 @default.
- W2548332911 cites W2011013717 @default.
- W2548332911 cites W2011578101 @default.
- W2548332911 cites W2018852632 @default.
- W2548332911 cites W2026412380 @default.
- W2548332911 cites W2044748199 @default.
- W2548332911 cites W2047274488 @default.
- W2548332911 cites W2052023059 @default.
- W2548332911 cites W2052252723 @default.
- W2548332911 cites W2053431870 @default.
- W2548332911 cites W2053597656 @default.
- W2548332911 cites W2056427606 @default.
- W2548332911 cites W2063543191 @default.
- W2548332911 cites W2064210857 @default.
- W2548332911 cites W2064510625 @default.
- W2548332911 cites W2071067871 @default.
- W2548332911 cites W2087829259 @default.
- W2548332911 cites W2090102465 @default.
- W2548332911 cites W2095597897 @default.
- W2548332911 cites W2107888400 @default.
- W2548332911 cites W2109520720 @default.
- W2548332911 cites W2111376288 @default.
- W2548332911 cites W2119493899 @default.
- W2548332911 cites W2124874779 @default.
- W2548332911 cites W2125413404 @default.
- W2548332911 cites W2127096996 @default.
- W2548332911 cites W2130447065 @default.
- W2548332911 cites W2135892517 @default.
- W2548332911 cites W2138251783 @default.
- W2548332911 cites W2144010669 @default.
- W2548332911 cites W2144905510 @default.
- W2548332911 cites W2146921865 @default.
- W2548332911 cites W2148524989 @default.
- W2548332911 cites W2151626292 @default.
- W2548332911 cites W2159571963 @default.
- W2548332911 cites W2161560844 @default.
- W2548332911 cites W2163404084 @default.
- W2548332911 cites W2318022415 @default.
- W2548332911 cites W2318719664 @default.
- W2548332911 cites W2411210867 @default.
- W2548332911 doi "https://doi.org/10.1016/j.ajme.2016.10.001" @default.
- W2548332911 hasPublicationYear "2017" @default.
- W2548332911 type Work @default.
- W2548332911 sameAs 2548332911 @default.
- W2548332911 citedByCount "0" @default.
- W2548332911 crossrefType "journal-article" @default.
- W2548332911 hasAuthorship W2548332911A5013929805 @default.
- W2548332911 hasAuthorship W2548332911A5037590928 @default.
- W2548332911 hasAuthorship W2548332911A5049722680 @default.
- W2548332911 hasAuthorship W2548332911A5078046174 @default.
- W2548332911 hasAuthorship W2548332911A5086760804 @default.
- W2548332911 hasAuthorship W2548332911A5091425909 @default.
- W2548332911 hasBestOaLocation W25483329111 @default.
- W2548332911 hasConcept C126322002 @default.
- W2548332911 hasConcept C142052008 @default.
- W2548332911 hasConcept C142462285 @default.
- W2548332911 hasConcept C142724271 @default.
- W2548332911 hasConcept C203014093 @default.
- W2548332911 hasConcept C2778607973 @default.
- W2548332911 hasConcept C2779357621 @default.
- W2548332911 hasConcept C2781069245 @default.
- W2548332911 hasConcept C2781413609 @default.
- W2548332911 hasConcept C3013748606 @default.
- W2548332911 hasConcept C39432304 @default.
- W2548332911 hasConcept C71924100 @default.
- W2548332911 hasConcept C91375879 @default.
- W2548332911 hasConceptScore W2548332911C126322002 @default.
- W2548332911 hasConceptScore W2548332911C142052008 @default.
- W2548332911 hasConceptScore W2548332911C142462285 @default.
- W2548332911 hasConceptScore W2548332911C142724271 @default.
- W2548332911 hasConceptScore W2548332911C203014093 @default.
- W2548332911 hasConceptScore W2548332911C2778607973 @default.
- W2548332911 hasConceptScore W2548332911C2779357621 @default.
- W2548332911 hasConceptScore W2548332911C2781069245 @default.
- W2548332911 hasConceptScore W2548332911C2781413609 @default.
- W2548332911 hasConceptScore W2548332911C3013748606 @default.
- W2548332911 hasConceptScore W2548332911C39432304 @default.
- W2548332911 hasConceptScore W2548332911C71924100 @default.
- W2548332911 hasConceptScore W2548332911C91375879 @default.
- W2548332911 hasIssue "3" @default.
- W2548332911 hasLocation W25483329111 @default.
- W2548332911 hasOpenAccess W2548332911 @default.
- W2548332911 hasPrimaryLocation W25483329111 @default.